Thurston Springer Miller Herd & Titak’s AbbVie ABBV Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	7,148 +3,090	+76%	+$665K	0.65%	29
2026 Q1	$883K	Sell	4,058 -3,607	-47%	-$800K	0.36%	66
2025 Q4	$1.75M	Buy	7,665 +6,946	+966%	+$1.58M	0.61%	32
2025 Q3	$166K	Sell	719 -12,158	-94%	-$2.48M	0.33%	96
2025 Q2	$2.39M	Buy	12,877 +2,205	+21%	+$410K	0.31%	88
2025 Q1	$2.24M	Buy	10,672 +462	+5%	+$89.8K	0.38%	72
2024 Q4	$1.81M	Buy	10,210 +1,392	+16%	+$256K	0.37%	68
2024 Q3	$1.74M	Sell	8,818 -257	-3%	-$48K	0.48%	50
2024 Q2	$1.56M	Sell	9,075 -38,810	-81%	-$6.43M	0.48%	46
2024 Q1	$8.72M	Buy	+47,885	New	+$8.25M	3.5%	7

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's ABBV Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak increased its AbbVie (ABBV) stake by 76% in Q2 2026, buying an estimated $665K and bringing the position to 7,148 shares worth $1.8M. The position accounts for 0.65% of the portfolio, ranked #29.

Thurston Springer Miller Herd & Titak first reported a position in ABBV in Q1 2024 and has held it in 10 quarters since. The position peaked at $8.72M in Q1 2024. 1,718 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Thurston Springer Miller Herd & Titak held 7,148 shares of AbbVie worth $1.8M as of Q2 2026.
Thurston Springer Miller Herd & Titak bought 3,090 AbbVie shares in Q2 2026, an estimated $665K.
AbbVie made up 0.65% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #29 holding.
Thurston Springer Miller Herd & Titak first reported a position in AbbVie in Q1 2024 and has held it in 10 quarters since.
Thurston Springer Miller Herd & Titak's AbbVie position peaked at $8.72M in Q1 2024.
1,718 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.